ClinicalTrials.gg
CompletedNCT05021835ZEUSUpdated Sep 28, 2026

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

A Phase 3 interventional study of Ziltivekimab B and Ziltivekimab C in Cardiovascular Risk, Chronic Kidney Disease and Inflammation, sponsored by Novo Nordisk A/S. Completed at 1,073 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Updated Sep 28, 20269 sites added7 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,385
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Novo Nordisk A/S.

Enrollment
Largest of 18
6,385 · median 128
Started
2021
with 3 others
Phase 3
5 of 29
1 open now
Registered
13th of 29
by date

Among the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 13th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Renal Insufficiency, Chronic by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.

Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same.

Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe.

Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly.

The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits.

Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram).

Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

03

Conditions studied

  • Cardiovascular Risk
  • Chronic Kidney Disease
  • Inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic kidney disease defined by one of the below:

    1. Estimated (eGFR) greater than or equal to (>=) 15 and below 60 mL/min/1.73 m\^2 (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation)
    2. Urinary albumin-to-creatinine ratio (UACR) >= 200 milligrams per gram (mg/g) and eGFR >= 60 mL/min/1.73 m2 (using the CKD-EPI creatinine equation)
  • Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligram per liter (mg/L)
  • Evidence of atherosclerotic cardiovascular disease (ASCVD) by one or more of the following:

    a) Coronary heart disease defined as at least one of the following: i. Documented history of MI ii. Prior coronary revascularisation procedure iii. greater than or equal to 50% stenosis in major epicardial coronary artery documented by cardiac catheterisation or CT coronary angiography b) Cerebrovascular disease defined as at least one of the following: i. Prior stroke of atherosclerotic origin ii. Prior carotid artery revascularisation procedure iii. greater than or equal to 50% stenosis in carotid artery documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound.

    c) Symptomatic peripheral artery disease (PAD) defined as at least one of the following: i. Intermittent claudication with an ankle-brachial index (ABI) below or equal to 0.90 at rest ii. Intermittent claudication with a greater than or equal to 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound iii. Prior peripheral artery (excluding carotid) revascularisation procedure iv. Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g. trauma or osteomyelitis).

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris, or within 60 days prior to randomisation (visit 2).
  • Planned coronary, carotid or peripheral artery revascularisation known on the day of randomisation (visit 2).
  • Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,385 participants (actual)

Study arms

  • Experimental
    Ziltivekimab

    Participants will receive Ziltivekimab B or Ziltivekimab C subcutaneously once monthly for up to 4 years.

    Drug: Ziltivekimab B · Drug: Ziltivekimab C

  • Placebo comparator
    Placebo

    Participants will receive either placebo (Ziltivekimab B) or placebo (Ziltivekimab C) subcutaneously once monthly for up to 4 years.

    Drug: Placebo (Ziltivekimab B) · Drug: Placebo (Ziltivekimab C)

Interventions

  • Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

  • Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

  • DrugPlacebo (Ziltivekimab B)

    Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

  • DrugPlacebo (Ziltivekimab C)

    Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months)

Secondary outcomes

  1. Time to first occurrence of expanded MACE, a composite endpoint consisting of: CV death, non-fatal MI, non-fatal stroke and hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months)

  2. Number of heart failure hospitalisations or urgent heart failure visits or CV deaths

    Count

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months)

  3. Time to first occurrence of a composite kidney endpoint consisting of: CV death, onset of persistent atleast 40 percent (%) reduction in eGFR (CKD-epidemiology collaboration [CKD-EPI]) compared with baseline, kidney failure

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months)

  4. Time to occurrence of all-cause mortality

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months)

  5. Time to first occurrence of each of the individual components of the expanded MACE endpoint and the kidney composite endpoint.

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  6. Time to first occurrence of MI (fatal and non-fatal).

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  7. Time to first occurrence of stroke (fatal and non-fatal).

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  8. Time to first occurrence of a composite MACE endpoint consisting of: all-cause mortality, non-fatal MI and non-fatal stroke

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  9. Time to first occurrence of a 4-component kidney endpoint consisting of: onset of persistent at least 40% reduction in eGFR (CKD-EPI) compared with baseline, kidney failure

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  10. Time to first occurrence of coronary revascularisation

    Months

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  11. Change in Urinary Abumin-to-Ceatinine ratio (UACR).

    Percentage

    Time frame: From randomisation (month 0) to 2 years (24 months).

  12. Change in eGFR (CKD-EPI))

    mL/min/1.73 m\^2

    Time frame: From randomisation (month 0) to 2 years (24 months)

  13. Annual rate of change in eGFR (CKD-EPI) (total eGFR slope)

    mL/min/1.73 m\^2/ year

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  14. Change in high-sensitivity C-reactive protein (hs-CRP)

    Percentage

    Time frame: From randomisation (month 0) to 2 years (24 months

  15. Change in N-terminal-pro-brain natriuretic peptide ( NT-pro-BNP)

    Percentage

    Time frame: From randomisation (month 0) to 2 years (24 months)

  16. Change in left ventricular ejection fraction (LVEF)

    Percentage

    Time frame: From randomisation (month 0) to 2 years (24 months)

  17. Number of events of atrial fibrillation

    Count

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  18. Change in haemoglobin

    Grams per deciliter (g/dL)

    Time frame: From randomisation (month 0) to 2 years (24 months)

  19. Number of hospitalisations with infection as primary cause or death due to infection.

    Count

    Time frame: From randomisation (month 0) to end-of-study (up to 48 months).

  20. Change in Short Form 36 (SF-36) Physical Component Score (PCS)

    Score on scale

    Time frame: From randomisation (month 0) to 2 years (24 months)

07

Study locations

1,073 sites
  • Uni of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Chambliss Clinical Trials LLC
    Montgomery, Alabama 36106, United States
  • Lenzmeier Fam Med CCT Research
    Glendale, Arizona 85308, United States
  • Aventiv Research Inc.
    Mesa, Arizona 85206, United States
  • Univ of Arkansas Med Sciences
    Little Rock, Arkansas 72205, United States
  • Unity Health-Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • National Heart Institute Cal
    Beverly Hills, California 90211, United States
  • California Inst Of Renal Res
    Chula Vista, California 91910, United States
  • California Institute of Renal Research #10
    Chula Vista, California 91910, United States
  • Valley Clinical Trials
    Covina, California 91723, United States
  • Valiance Clinical Research
    Huntington Park, California 90255, United States
  • Scripps Wht Diab Inst La Jolla
    La Jolla, California 92037, United States
  • Balboa Nephro Med Gr Inc LaMes
    La Mesa, California 91942, United States
  • First Valley Medical Group
    Lancaster, California 93534, United States
  • VA Loma Linda Hlthcr Sys
    Loma Linda, California 92357, United States
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
  • Angel City Research, Inc.
    Los Angeles, California 90010, United States
  • North America Research Institute
    Lynwood, California 90262, United States
  • Hoag Medical Group
    Newport Beach, California 92663, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Desert Oasis Hlthcr Med Group
    Palm Springs, California 92262, United States
  • Riverside Nephrology Physicians
    Riverside, California 92504, United States
  • N America Res Inst - San Dimas
    San Dimas, California 91773, United States
  • Lundquist Inst-Biomed Innovtn
    Torrance, California 90502, United States
  • Denver Health Outpatient Medical Center
    Denver, Colorado 80204, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • VA-Connecticut (VACHS)
    West Haven, Connecticut 06516, United States
  • George Washington Uni Med
    Washington D.C., District of Columbia 20037, United States
  • Excel Med Ctr Clinical Trials
    Boca Raton, Florida 33434, United States
  • Florida Premier Cardiology
    Boynton Beach, Florida 33437, United States
  • Innovative Research of W FL
    Clearwater, Florida 33756, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • Integrative Research Assoc Inc
    Fort Lauderdale, Florida 33312, United States
  • Elixia Pines
    Hollywood, Florida 33024, United States
  • Encore Medical Research LLC
    Hollywood, Florida 33024, United States
  • Northeast Research Institute
    Jacksonville, Florida 32204, United States
  • Est Cst Inst for Rsrch,Jksnvil
    Jacksonville, Florida 32216, United States
  • Baptist Heart Specialists
    Jacksonville, Florida 32258, United States
  • Clinical Research of Cent FL
    Lakeland, Florida 33805, United States
  • Pharmax Research Clinic
    Miami, Florida 33126, United States
  • Life Spring Research Foundation LLC
    Miami, Florida 33130, United States
  • Allied Biomedical Research
    Miami, Florida 33155, United States
  • San Marcus Res Clin Miami Lakes
    Miami Lakes, Florida 33014, United States
  • Office of Kenneth Blaze DO
    Miramar, Florida 33027, United States
  • Suncoast Clin Res Port Richey
    New Port Richey, Florida 34652, United States
  • Suncoast Clinical Research, Inc.
    Palm Harbor, Florida 34684, United States
  • A&R Research Group, LLC
    Pembroke Pines, Florida 33024, United States
  • Hanson Clinical Research Center
    Port Charlotte, Florida 33952, United States
  • Peace River Cardiovascular Center
    Port Charlotte, Florida 33952, United States
  • Northeast Research Institute
    Saint Augustine, Florida 32080, United States
  • East Coast Institute for Research LLC_St. Augustine
    Saint Augustine, Florida 32086, United States
  • St Johns Center for Clin. Res
    Saint Augustine, Florida 32086, United States
  • Javara/Privia Med Grp GA,LLC
    Albany, Georgia 31707, United States
  • Southeastern Clinical R.I.
    Augusta, Georgia 30904, United States
  • Southeastern Clinical Research Institute, LLC
    Augusta, Georgia 30904, United States
  • Hope Clin Res & Wellness
    Conyers, Georgia 30094, United States
  • Javara Inc._Albany
    Fayetteville, Georgia 30214, United States
  • NSC Research, Inc
    Johns Creek, Georgia 30024, United States
  • Endo Res Solutions Inc
    Roswell, Georgia 30076, United States
  • Javara Inc._Winston Salem
    Savannah, Georgia 31406, United States
  • Saltzer Medical Group Research
    Nampa, Idaho 83686-6011, United States
  • Endeavor Health Clinical Operations-NCH
    Arlington Heights, Illinois 60005, United States
  • Research by Design LLC
    Chicago, Illinois 60643, United States
  • Clinical Invest Special_Gurnee
    Gurnee, Illinois 60031, United States
  • Chicago Medical Research LLC
    Hazel Crest, Illinois 60429, United States
  • Endeavor Health
    Skokie, Illinois 60077, United States
  • Central Illinois Diabetes and Clinical Research
    Springfield, Illinois 62711, United States
  • Clin Invest Spec, Inc
    Wauconda, Illinois 60084, United States
  • MediSphere Medical RC
    Evansville, Indiana 47714, United States
  • Velocity Clin. Res Valparaiso
    Valparaiso, Indiana 46383, United States
  • Midwest Heart & Vasc Spec
    Overland Park, Kansas 66211, United States
  • Cotton O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • Lexington VA Health Care System
    Lexington, Kentucky 40502, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • Norton Heart Specialists-Springs
    Louisville, Kentucky 40205, United States
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
  • Clinical Trials of Ame, LLC
    Monroe, Louisiana 71201, United States
  • IMA Clinical Research
    Monroe, Louisiana 71201, United States
  • Grace Research, LLC_Shreveport
    Shreveport, Louisiana 71105, United States
  • Louisiana Heart Center_Slidell
    Slidell, Louisiana 70458, United States
  • Anne Arundel Medical Center
    Annapolis, Maryland 21401, United States
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
  • John P Hakim MD and Associates
    Clinton, Maryland 20735, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115-5804, United States
  • Mass General Community Physicians
    Haverhill, Massachusetts 01830, United States
  • Henry Ford Hospital_Detroit
    Detroit, Michigan 48202, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Healthy Heart Cardiology
    Grand Rapids, Michigan 49546, United States
  • McLaren Northern MI Hosp
    Petoskey, Michigan 49770, United States
  • AHS dba Abbot NW Hosp Diab Cen
    Minneapolis, Minnesota 55407, United States
  • University of Minnesota_Minneapolis_1
    Minneapolis, Minnesota 55455, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Gateway CV Research Cntr Inc.
    St Louis, Missouri 63128, United States
  • St Louis Heart & Vascular, P.C.
    St Louis, Missouri 63136, United States
  • Nebraska Heart Institute_Lincoln
    Lincoln, Nebraska 68526, United States
  • VA NEB - Western IA Health Stm
    Omaha, Nebraska 68105, United States
  • Methodist Phys Clin Heart Cons
    Omaha, Nebraska 68114, United States
  • Univ of Nebraska Medical CTR
    Omaha, Nebraska 68198-3020, United States
  • University of Nevada School of Medicine
    Las Vegas, Nevada 89102, United States
  • Palm Research Center Inc-Vegas
    Las Vegas, Nevada 89128, United States

Showing the first 100 of 1,073 sites across 38 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Byambaa E, Roshanravan B, Berglund L. Lipoprotein(a) and CKD: Insights into New Therapeutic Opportunities. Clin J Am Soc Nephrol. 2026 Aug 1;21(8):1469-1481. doi: 10.2215/CJN.0000000968. Epub 2025 Dec 2. PubMed 41329869 ↗
  • In Het Panhuis W, Thiemann E, van Dijk DMAH, Been B, Jarrett KE, Meurs A, Kooijman S, Hovingh MV, Modder M, van Os BW, Sluiter TJ, Blomberg N, Pronk ACM, Afkir S, Streefland TCM, Lalai RA, Taveras MO, Zhang S, Adams TE, Terry LV, Turpin-Nolan SM, de Vries MR, Giera M, Rose-John S, Zelcer N, de Boer JF, de Aguiar Vallim TQ, Febbraio MA, Rensen PCN, Schonke M. The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice. Sci Adv. 2025 Oct 24;11(43):eadx3794. doi: 10.1126/sciadv.adx3794. Epub 2025 Oct 24. PubMed 41134879 ↗
  • Mohammadnia N, van Broekhoven A, Bax WA, Eikelboom JW, Mosterd A, Fiolet ATL, Tijssen JGP, Thompson PL, de Kleijn DPV, Tsimikas S, Cornel JH, Yeang C, El Messaoudi S. Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort. Atherosclerosis. 2025 Jun;405:119211. doi: 10.1016/j.atherosclerosis.2025.119211. Epub 2025 Apr 26. PubMed 40318255 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jun 2026, 57 months.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 57 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Aug 26, 2021
StartActual
Aug 30, 2021
Primary completionActual
Jun 9, 2026
CompletionActual
Jun 9, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 7 sites removed
Show 9 added (5 China, 2 Brazil, 1 United States, 1 United Kingdom)
  • Baylor College Of Medicine_Houston, Travis Street · Houston, United States
  • Hospital do Coração do Brasil - Rede Do'r · Brasília, Brazil
  • Grupo AngioKormann · Blumenau, Brazil
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology - Cardiology · Wuhan, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology-Cardiology · Wuhan, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology-Nephrology · Wuhan, China
  • The Second Norman Bethune Hospital of Jilin University-Nephrology · Changchun, China
  • Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Affiliated Hospital of UESTC-Nephrology · Chengdu, China
  • The Health Centre · Bradford on Avon, United Kingdom
Show 7 removed
  • Baylor College Of Medicine_Houston-Travis Street · Houston, United States
  • Hospital do Coração do Brasil · Brasília, Brazil
  • Wuhan Union Hospital-Cardiology · Wuhan, China
  • Tongji Hospital, Tongji Medical College of HUST-Cardiology · Wuhan, China
  • The Second Hospital of Jilin University-Nephrology · Changchun, China
  • Sichuan Provincial People's Hospital- Nephrology · Chengdu, China
  • The Health Centre · Bradford-on-Avon, United Kingdom
Sep 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41134879 ↗
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41134879 ↗
    9 sites added, 7 sites removed
    Show 9 added (5 China, 2 Brazil, 1 United States, 1 United Kingdom)
    • Baylor College Of Medicine_Houston, Travis Street · Houston, United States
    • Hospital do Coração do Brasil - Rede Do'r · Brasília, Brazil
    • Grupo AngioKormann · Blumenau, Brazil
    • Union Hospital Tongji Medical College Huazhong University of Science and Technology - Cardiology · Wuhan, China
    • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology-Cardiology · Wuhan, China
    • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology-Nephrology · Wuhan, China
    • The Second Norman Bethune Hospital of Jilin University-Nephrology · Changchun, China
    • Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Affiliated Hospital of UESTC-Nephrology · Chengdu, China
    • The Health Centre · Bradford on Avon, United Kingdom
    Show 7 removed
    • Baylor College Of Medicine_Houston-Travis Street · Houston, United States
    • Hospital do Coração do Brasil · Brasília, Brazil
    • Wuhan Union Hospital-Cardiology · Wuhan, China
    • Tongji Hospital, Tongji Medical College of HUST-Cardiology · Wuhan, China
    • The Second Hospital of Jilin University-Nephrology · Changchun, China
    • Sichuan Provincial People's Hospital- Nephrology · Chengdu, China
    • The Health Centre · Bradford-on-Avon, United Kingdom
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05021835
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 26, 2021
Start date
Aug 30, 2021
Primary completion
Jun 9, 2026
Completion
Jun 9, 2026
Last update
Sep 28, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion